In response to the recent declaration by the World Health Organization (WHO) classifying the mpox outbreak as a public health emergency of international concern, Roche has announced its commitment to enhance laboratory capacities globally for mpox testing. This announcement came as the new strain of mpox, identified as clade 1b, emerges rapidly in the Democratic Republic of the Congo (DRC) and starts to spread to neighboring countries.
The WHO has highlighted the urgency of a coordinated international response to control the outbreaks, indicating extensive collaboration is essential. Following this, Roche is collaborating with governments, healthcare entities, and various organizations to bolster efforts against the mpox spread. This includes providing training for laboratory operations across Africa, facilitated through their South African campus, as well as locally within affected regions.
The clade 1b strain of mpox, identified recently as more virulent than previous strains seen in the U.S. during 2022, has its epicenter in the DRC and was first recorded in September 2023. As of the latest reports, this newer, more aggressive strain has not only impacted the DRC but has also crossed borders into Burundi, Kenya, Rwanda, and Uganda. These countries have reported their initial cases, presenting a challenging scenario as the virus advances through household and community transmission.
Recognizing the severity of the ongoing crisis, both the WHO and the Africa Centres for Disease Control and Prevention have officially declared public health emergencies. This has prompted other major health organizations, such as the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), to outline their emergency responses.
In a bid to facilitate prompt and efficient diagnosis, Roche was among the first to have an mpox test authorized under emergency use in the U.S. This test is suitable for Roche’s Cobas 6800/8800 systems and was approved in November 2022. Additionally, Roche has developed PCR mpox assays applicable via their Lightcycler 480 II instrument, Lightcycler PRO, and Cobas z 480 analyzer. This diagnostic expansion is crucial in managing and curbing the spread of the virus effectively.
In tandem, other laboratory services such as Abbott, Labcorp, and Quest Diagnostics have received authorization for their mpox testing products, easing some of the burden on diagnostic requirements. Together, this network of corporate and laboratory collaborations plays a pivotal role in addressing the outbreak through timely and widespread testing.
Currently, in the U.S., mpox, specifically the DRC-originating clade 1b strain, is under close observation despite there being no known cases. The CDC has reassured the public that the U.S. is well-equipped to detect, contain, and manage cases of the clade 1 strain should they arise domestically. The agency reported that preparations to handle this new strain began in December, and the actual risk to the general American population remains very low.
In sum, as the new strain of mpox poses a heightened global health threat, robust international cooperation and swift action in testing and diagnostics spearheaded by Roche and supported by global healthcare institutions are critical in mitigating the spread and impact of the disease. Through these concerted efforts, there is a structured pathway to manage not only the immediate effects of the outbreaks but also to safeguard global health security against potential future escalations.
#Roche #increase #global #laboratory #capacity #mpox #testing
